Sensitivity of White Blood Cell DNA to Damage from UV Light Distinguishes Cancer Patients from Healthy Individuals
|
By LabMedica International staff writers Posted on 13 Aug 2014 |

Image: The single cell gel electrophoresis assay or “comet” test (Photo courtesy of the Belgian BioElectroMagnetics Group).
A simple test that measures the extent of damage to white blood cell DNA caused by exposure to ultraviolet light has the potential to detect individuals with cancer before the appearance of any detectable symptoms.
Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).
The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.
For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.
Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.
Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”
“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”
The study was published in the July 25, 2014, online edition of FASEB Journal.
Related Links:
University of Bradford
Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).
The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.
For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.
Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.
Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”
“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”
The study was published in the July 25, 2014, online edition of FASEB Journal.
Related Links:
University of Bradford
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







